Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Double-blind, Two-cycle, Two-way Crossover Phase Ib Study to Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis

NCT05607446 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT05607446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05607446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Double-blind, Two-cycle, Two-way Crossover Phase Ib Study to Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
September 14, 2022
Completion date
December 14, 2023
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis